论文部分内容阅读
目的:研究hIL-10和HGF重组体对大鼠活体肝移植术后急性排斥反应的抑制作用。方法:以DA大鼠(RT1a)为供体,Lewis大鼠(RT1l)为受体建立异种肝移植鼠模型,实验组于移植后1天及7天,腹腔内注射T-HGF和T-hIL-10重组体(100μg/ml)100μl,对照组注射等量生理盐水。移植后1,7,10,20天取大鼠尾静脉血,ELISA法测定血清HGF、IL-10水平,RT-PCR测定肝细胞HGF、IL-10mRNA的表达水平,常规肝功能测定,活体肝移植动物生存期观测。结果:实验组鼠肝细胞有HGF和IL-10mRNA表达,对照组肝细胞未见表达。对照组大鼠HGF和IL-10水平一直维持在较低水平,实验组大鼠HGF和IL-10水平明显高于对照组(P<0.05)。注射重组体的实验组平均生存时间为(19±0.9)天,20天时存活只数为6只,存活率75%;对照组平均生存时间为(8.6±0.5)天,20天时存活只数为2只,存活率75%(P<0.05)。对照组未注射重组体,ALT和AST值持续升高,注射重组体后ALT和AST值亦有升高,但明显低于对照组(p<0.05)。结论:活体肝移植大鼠导入IL-10和HGF基因重组体后可抑制移植术后急性排斥反应。
OBJECTIVE: To study the inhibitory effect of recombinant hIL-10 and HGF on acute rejection after living donor liver transplantation in rats. Methods: The rat model of xenotransplantation was established with Lewis rats (RT1a) as donor and Lewis rats (RT1l) as recipients. T-HGF and T-hIL were injected intraperitoneally 1 day and 7 days after transplantation in experimental group -10 recombinant (100μg / ml) 100μl, the control group injected with normal saline. The rats were sacrificed on the 1st, 10th, 10th, 20th day after transplantation. The levels of HGF and IL-10 in serum were measured by ELISA. The expression of HGF and IL-10 mRNA in hepatocytes were determined by RT-PCR. Survival of transplant animals observed. Results: The expression of HGF and IL-10 mRNA in hepatocytes of experimental group was not observed. The levels of HGF and IL-10 in the control group were kept at a low level. The levels of HGF and IL-10 in the experimental group were significantly higher than those in the control group (P <0.05). The average survival time of experimental group injected with recombinant was (19 ± 0.9) days, and the number of surviving was only 75% after 20 days. The average survival time of control group was (8.6 ± 0.5) days. 2, survival rate 75% (P <0.05). In the control group, the ALT and AST values kept increasing. The ALT and AST values were also increased after injection of the recombinant, but were significantly lower than those in the control group (p <0.05). CONCLUSION: Transplantation of IL-10 and HGF gene recombinants in living-donor liver transplantation can inhibit the acute rejection after transplantation.